Hypofractionated high-dose radiation therapy for prostate cancer: Long-term results of a multi-institutional phase II trial

International Journal of Radiation Oncology Biology Physics

Volumn 84, Issue 4, 2012, Pages

  Fonteyne, Valérie ^a   Soete, Guy ^b   Arcangeli, Stefano ^c   De Neve, Wilfried ^a   Rappe, Bernard ^d   Storme, Guy ^b   Strigari, Lidia ^c   Arcangeli, Giorgio ^c   De Meerleer, Gert ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d Algemeen Stedelijk Ziekenhuis   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; MULTIVARIANT ANALYSIS; TOXICITY; UROLOGY;

BIOCHEMICAL FAILURE; BIOCHEMICAL OUTCOME; GENITOURINARY TOXICITIES; LONG-TERM RESULTS; METHODS AND MATERIALS; MULTI VARIATE ANALYSIS; PREDICTIVE FACTORS; RADIATION THERAPY ONCOLOGY GROUPS;

RADIOTHERAPY;

BICALUTAMIDE; ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FOLLOW UP; GASTROINTESTINAL TOXICITY; GYNECOMASTIA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOCTURIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POLYURIA; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RECTUM HEMORRHAGE; TRANSURETHRAL RESECTION; URETHRA STENOSIS; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; ANALYSIS OF VARIANCE; BLADDER; BLOOD; FEMUR HEAD; GASTROINTESTINAL TRACT; INCIDENCE; ITALY; MICTURITION DISORDER; MIDDLE AGED; ORGANS AT RISK; PROSPECTIVE STUDY; PROSTATE TUMOR; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RADIATION INJURY; RADIOGRAPHY; RECTUM; TIME; UROGENITAL SYSTEM;

ADULT; AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; DOSE FRACTIONATION; FEMUR HEAD; GASTROINTESTINAL TRACT; HUMANS; INCIDENCE; ITALY; MALE; MIDDLE AGED; ORGANS AT RISK; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RECTUM; TIME FACTORS; URINARY BLADDER; URINATION DISORDERS; UROGENITAL SYSTEM;

EID: 84872047075     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.04.012     Document Type: Article

References (22)

1. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8: 475-487.
2. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 2010; 28: 1106-1111.
3. Thames HD Jr., Withers HR, Peters LJ, et al. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 1982; 8: 219-226.
4. Fowler JF, Ritter MA, Chappell RJ, et al. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 2003; 56: 1093-1104.
5. Yeoh EE, Botten RJ, Butters J, et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 2010; 81: 1271-1278.
6. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006; 64: 518-526.
7. Roach M III. Re: the use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 1923-1924.
8. Villeirs GM, Van Vaerenbergh K, Vakaet L, et al. Interobserver delineation variation using CT versus combined CT + MRI in intensity-modulated radiotherapy for prostate cancer. Strahlenther Onkol 2005; 181: 424-430.
9. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-1346.
10. LENT SOMA tables. Radiother Oncol 1995; 35: 17-60.
11. Barry MJ, Fowler FJ Jr., O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-1557.
12. Arcangeli G, Saracino B, Gomellini S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010; 78: 11-18.
13. Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005; 23: 6132-6138.
14. Zilli T, Jorcano S, Rouzaud M, et al. Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement: toxicity and outcome from a dose escalation pilot study. Int J Radiat Oncol Biol Phys 2011; 81: 382-389.
15. Martin JM, RosewallT, Bayley A, et al. PhaseII trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007; 69: 1084-1089.
16. Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007; 68: 1424-1430.
17. Arcangeli G, Fowler J, Gomellini S, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011; 79: 1013-1021.
18. Dearnaley D, Syndikus I, Sumo G, et al. Conventional versus hypo-fractionated high-dose intensity-modultaed radiotherapy for prostate cancer: preliminary results from the CHHiP randomised controlled trial. Lancet Oncol 2012; 13: 43-54.
19. Di Staso M, Bonfili P, Gravina GL, et al. Late morbidity and oncological outcome after radical hypofractionated radiotherapy in men with prostate cancer. BJU Int 2010; 106: 1458-1462.
20. Lock M, Best L, Wong E, et al. A Phase II trial of arc-based hypo-fractionated intensity-modulated radiotherapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1306-1315.
21. Madsen BL, Hsi RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007; 67: 1099-1105.
22. Yassa M, Fortin B, Fortin MA, et al. Combined hypofractionated radiation and hormone therapy for the treatment of intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2008; 71: 58-63.